Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Leukemia 17Breast Neoplasms 14Rectal Neoplasms 7Neoplastic Cells, Circulating 7Lung Neoplasms 7Leukemia, Myeloid, Acute 7Colorectal Neoplasms 7Colonic Neoplasms 7Prostatic Neoplasms 6Head and Neck Neoplasms 6Kidney Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Squamous Cell Carcinoma of Head and Neck 4Sarcoma 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Multiple Myeloma 4Congenital Abnormalities 4Wilms Tumor 3Neoplasms, Plasma Cell 3Carcinoma, Renal Cell 3Carcinoma, Intraductal, Noninfiltrating 3Unspecified Adult Solid Tumor, Protocol Specific 2Ovarian Neoplasms 2Melanoma 2Leukemia, Myelomonocytic, Acute 2Leukemia, Monocytic, Acute 2Leukemia, Megakaryoblastic, Acute 2Leukemia, Erythroblastic, Acute 2Esophageal Neoplasms 2Endometrial Neoplasms 2

Interventions

Doxorubicin 17Echocardiography 14Exercise 9Cyclophosphamide 9Trastuzumab 8Dexrazoxane 8Electrocardiography 7Razoxane 6Carvedilol 6Vincristine 4Radiotherapy 4Filgrastim 4Docetaxel 4Methotrexate 3Granulocyte Colony-Stimulating Factor 3Etoposide 3Cisplatin 3Atorvastatin 3salicylhydroxamic acid 2sacubitril and valsartan sodium hydrate drug combination 2empagliflozin 2dapagliflozin 2Tablets 2Social Determinants of Health 2Silymarin 2Prednisone 2Paclitaxel 2Neoadjuvant Therapy 2Magnetic Resonance Spectroscopy 2Leucovorin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cardiotoxicity × Reverse Transcriptase Polymerase Chain Reaction × Clear all
NCT00436566 2022-08-05

Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery

Mayo Clinic

Phase 2 Completed
122 enrolled 22 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡